TabbFORUM in interview with Jordan Hu, CEO of RiskVal
Managing OTC Derivatives Risk on the Buy Side: Jordan Hu, RiskVal
23 February 2018 — While regulation is driving some standardization of over-the-counter derivatives, how these products are assembled and traded is becoming more complicated, particularly for the buy side. According to Jordan Hu, RiskVal, intensifying regulatory requirements along with the emergence of new venues and liquidity pools are increasing the complexity of trading for the buy side and driving up costs. Speaking with TABB Group founder and research chairman Larry Tabb, Hu discusses how the buy side can leverage pre-trade analytics to navigate the OTC market, manage risk and target alpha, as well as the role of post-trade analytics in improving portfolio performance and efficiency and the future of SEF trading.
TabbFORUM is an open community that provides a platform for capital markets professionals to share their ideas and thought leadership with their peers. The views and opinions expressed are solely those of the author(s). They do not necessarily reflect the opinions of TABB Group, its analysts, TabbFORUM and its editors, or their employees, affiliates and partners.